Oral Vaccines Market Report give our customers an exhaustive and top to bottom examination

The global market for oral vaccines is primarily driven by increasing prevalence of infectious diseases in developing countries, bioterrorism, resistance to existing vaccines, etc. In addition to this, patient adherence to needle-free vaccine regime, preference to oral vaccines by children and geriatric population, cost effective nature, recent FDA approvals to oral vaccines for diseases such as cholera etc. are some of the factors expected to fuel the growth of global oral vaccines market. However, compromised immunogenicity in children and cost for maintaining a cold chain, inaccessibility in remote areas etc. are some of the factors limiting growth of global oral vaccines market.

The development of innovative delivery systems for oral vaccines may result in increased product efficiency and a lower failure rate for clinical trials. The development of low-cost oral vaccines for new indications not yet covered by existing vaccines is a great opportunity for researchers in this field, since it may enhance immunisation uptake in countries with limited access to immunisation. Several oral vaccination formulations are currently being examined in clinical trials, but their efficacy requires more comprehensive human investigations.

The global oral vaccines market has been segmented by product type into live attenuated vaccines, killed/inactivated vaccines, recombinant vaccines, and others (ribosomal fractions, antigenic preparations). Due to increased adoption for safety and efficacy, the killed/inactivates vaccines segment is predicted to occupy the largest proportion of the global market among all product types.

Based on end user, the global oral vaccines market has been classified as hospitals, clinics, government vaccination centers, and research institutes. Government vaccination centers are expected to contribute highest market share in the global oral vaccines market due to strong patient pool towards national immunization programs.

Key players operating in the global oral vaccines market include GlaxoSmithKline, Sanofi, Merck, Serum Institute of India pvt ltd, Swiss serum and vaccine institute Brene, Janssen pharmaceuticals, Paxvax corporation ltd, Valneva Canada, Shanghai Bravo bio Co ltd, Abbott Biologicals, MSD, Novavax, and Takeda.